- Home
- MIRM vs HXL Comparison
MIRM vs HXL Comparison
Compare MIRM & HXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | HXL |
|---|---|---|
| Founded | 2018 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.8B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MIRM | HXL |
|---|---|---|
| Price | $101.26 | $89.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $119.85 | $88.30 |
| AVG Volume (30 Days) | ★ 1.0M | 826.3K |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.80% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,138,000.00 | ★ $1,893,900,000.00 |
| Revenue This Year | $26.22 | $10.09 |
| Revenue Next Year | $22.04 | $12.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.50 | $51.94 |
| 52 Week High | $114.99 | $98.26 |
Technical Indicators
Market Signals| Indicator | MIRM | HXL |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 51.36 |
| Support Level | $95.68 | $88.83 |
| Resistance Level | $107.51 | $95.94 |
| Average True Range (ATR) | 5.22 | 3.09 |
| MACD | -0.65 | -0.35 |
| Stochastic Oscillator | 33.42 | 57.12 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About HXL Hexcel Corporation
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.